0
How does Myriad conduct BART testing?
- 1 people answered
0 Vote
1 Contributor
1693 Views 
0 Saved
0 Vote 1 Contributor1693 Views 0 SavedYou might also be interested in
It depends on the country. Overdiagnosis relates to the finding of a cancer that doesn’t act in a life-limiting way. Since the beginning of mammography and PSA eras we have diagnosed a lot of such disease.Mammography has not changed the percentage of women who have metastatic disease, rather it has ....
Two tests may be better than one. That’s the conclusion of researchers in a new study that looked at the reliability of both ultrasounds and mammograms. Where mammography is available, ultrasound should be seen as a supplemental test for women with dense breasts who do not meet high-risk criteria....
A benign tumor means it’s not cancer. These tumors don’t spread to other parts of the body and are usually not life-threatening. However, depending on their size or location, they may need to be removed if they press on important organs or cause discomfort.
Mahima Chaudhary
Imagine going in for a cancer screening, and the technician turns to you and says, "We're finished, but if I push this button over here, the machine can detect even smaller cancers. But here's the hitch: You have to pay $700 if you want me to push this button."
Myriad Genetics is doing something very similar with BART tests that determine if a woman has a potentially dangerous genetic abnormality linked to breast cancers.
When testing shows that a woman carries a bad gene, she has a much higher chance of getting breast cancer. These women usually then get more frequent MRIs, ultrasounds and mammograms to detect cancer.
Myriad owns the patent on breast cancer genes and so is the only company that can test for them. It offers one test that catches most, but not all, abnormalities, and then charges nearly all patients $700 for a second test that catches the rest.
If a woman can't afford the $700 fee, she may miss an abnormality, which could mean the difference between life and death.
Myriad defends the $700 charge for its second test, called BART, even though many patients can't afford it and insurance won't pay for it.